Researchers at Northwestern University and the Myelin Repair Foundation have simplified an autologous cell-based strategy for promoting antigen-specific tolerance by replacing splenic leukocytes with synthetic microparticles as the antigen carrier. The groups are planning to first develop the therapy and establish proof of concept in autoimmune indications for which the key antigen is known before moving forward in MS.